Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies Academic Article uri icon

Overview

MeSH Major

  • Antigens, CD274
  • Antineoplastic Combined Chemotherapy Protocols
  • Melanoma
  • Mucous Membrane
  • Programmed Cell Death 1 Receptor
  • Uveal Neoplasms

abstract

  • PD-1 and PD-L1 antibodies rarely confer durable remissions in patients with metastatic uveal melanoma. Clinical trial enrollment should be prioritized in this population. Cancer 2016;122:3344-3353. © 2016 American Cancer Society.

publication date

  • November 15, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.30258

PubMed ID

  • 27533448

Additional Document Info

start page

  • 3344

end page

  • 3353

volume

  • 122

number

  • 21